PFM Health Sciences, LP - BIOMARIN PHARMACEUTICAL INC ownership

BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 63 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
PFM Health Sciences, LP ownership history of BIOMARIN PHARMACEUTICAL INC
ValueSharesWeighting
Q3 2023$14,587,500
-1.2%
15,000,0000.0%0.69%
+19.7%
Q2 2023$14,771,520
-4.3%
15,000,0000.0%0.57%
-15.7%
Q1 2023$15,427,185
-59.6%
15,000,000
-58.2%
0.68%
-50.2%
Q4 2022$38,201,058
-16.2%
35,910,000
-21.8%
1.37%
-17.1%
Q3 2022$45,604,000
+0.1%
45,910,0000.0%1.65%
-5.1%
Q2 2022$45,566,000
-0.9%
45,910,0000.0%1.74%
+1.0%
Q1 2022$46,002,000
-4.4%
45,910,0000.0%1.72%
+5.0%
Q4 2021$48,118,000
+0.9%
45,910,0000.0%1.64%
+16.8%
Q3 2021$47,675,000
-0.3%
45,910,0000.0%1.40%
-6.5%
Q2 2021$47,834,000
+1.0%
45,910,0000.0%1.50%
+3.7%
Q1 2021$47,356,000
+9.6%
45,910,000
+13.9%
1.45%
-4.9%
Q4 2020$43,210,000
+2.0%
40,300,0000.0%1.52%
-22.4%
Q3 2020$42,361,000
-17.3%
40,300,000
-3.1%
1.96%
-26.2%
Q2 2020$51,199,000
+17.9%
41,600,0000.0%2.66%
-25.5%
Q1 2020$43,421,00041,600,0003.57%
Other shareholders
BIOMARIN PHARMACEUTICAL INC shareholders Q3 2023
NameSharesValueWeighting ↓
SHENKMAN CAPITAL MANAGEMENT INC 30,138,000$29,510,0003.72%
PFM Health Sciences, LP 45,910,000$46,002,0001.72%
Cheyne Capital Management (UK) LLP 2,320,000$2,330,0001.47%
ADVENT CAPITAL MANAGEMENT /DE/ 41,077,000$41,277,0000.66%
SSI INVESTMENT MANAGEMENT LLC 9,071,000$9,068,0000.50%
PALISADE CAPITAL MANAGEMENT, LP 14,548,000$14,612,0000.34%
RWC Asset Management LLP 7,500,000$7,552,0000.21%
KBC Group NV 400,000$40,316,0000.15%
PROSPECTOR PARTNERS LLC 1,000,000$1,000,0000.12%
MACKAY SHIELDS LLC 11,822,000$11,816,0000.10%
View complete list of BIOMARIN PHARMACEUTICAL INC shareholders